News items for the week of Nov. 11.
The company also said that it has acquired Beijing-based food safety testing firm Meizheng Group. The deal is expected to expand PerkinElmer's food safety capabilities.
The credit facility, available through Sept. 17, 2024, replaces a prior credit facility dated Aug. 11, 2016 for $1 billion.
The firm said that on Oct. 13 it will redeem all of its outstanding 5 percent unsecured notes due in 2021.
About $770 million in net proceeds will go toward the repayment of outstanding debt under its senior unsecured revolving credit facility.
The new method may be useful in future noninvasive prenatal tests that rely on the analysis of DNA from fetal cells instead of cell-free fetal DNA.
The index, which underperformed the Dow Jones and the Nasdaq, gave back the 11 percent gain it made in June.
The company's diagnostics segment's revenues were up 6 percent, while its discovery and analytical solutions segment's revenues grew less than 1 percent.
The firms aim to combine PerkinElmer 's Ordered Data Interpretation Network and FDNA's Face2Gene facial analysis software to target emerging markets.
FDNA has developed software called Face2Gene that uses facial anomalies, phenotypic traits, and variant information to diagnose genetic disorders.
GenomeWeb reports that Veritas Genetics is suspending its US operations.
A Brazilian-led team of researchers reports it has generated a sugarcane genome assembly that encompasses more than 99 percent of its genome.
Certain plasma proteins could be used to gauge a person's age and whether they are aging well, according to HealthDay News.
In Science this week: approach to measure microRNA targeting efficiency, strategy to conduct high-throughput chemical screens at single-cell resolution, and more.